Concepts (284)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 30 | 2006 | 1250 | 0.680 |
Why?
|
| Brain Neoplasms | 24 | 2013 | 1219 | 0.670 |
Why?
|
| Sarcoma | 11 | 1998 | 197 | 0.470 |
Why?
|
| Survivors | 3 | 2022 | 344 | 0.470 |
Why?
|
| Bone Neoplasms | 11 | 1996 | 427 | 0.470 |
Why?
|
| Sarcoma, Ewing | 10 | 1996 | 113 | 0.460 |
Why?
|
| Soft Tissue Neoplasms | 8 | 1996 | 131 | 0.410 |
Why?
|
| Ependymoma | 8 | 2013 | 131 | 0.310 |
Why?
|
| Cyclophosphamide | 6 | 2005 | 424 | 0.300 |
Why?
|
| Neoplasms | 8 | 2022 | 2753 | 0.280 |
Why?
|
| Rhabdomyosarcoma | 10 | 1996 | 194 | 0.270 |
Why?
|
| Antineoplastic Agents | 7 | 2013 | 1680 | 0.250 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2005 | 91 | 0.240 |
Why?
|
| Work Schedule Tolerance | 1 | 2003 | 37 | 0.220 |
Why?
|
| Child, Preschool | 38 | 2014 | 13802 | 0.200 |
Why?
|
| Burnout, Professional | 1 | 2003 | 114 | 0.200 |
Why?
|
| Combined Modality Therapy | 21 | 1999 | 1243 | 0.190 |
Why?
|
| Doxorubicin | 5 | 1996 | 307 | 0.180 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 169 | 0.180 |
Why?
|
| Internet | 2 | 2022 | 373 | 0.160 |
Why?
|
| Stress, Psychological | 1 | 2003 | 555 | 0.160 |
Why?
|
| Thiotepa | 2 | 1995 | 15 | 0.150 |
Why?
|
| Kidney Tubules | 6 | 1987 | 84 | 0.150 |
Why?
|
| Thrombocytopenia | 2 | 1996 | 229 | 0.140 |
Why?
|
| Child | 37 | 2022 | 24081 | 0.140 |
Why?
|
| Agranulocytosis | 1 | 1996 | 14 | 0.130 |
Why?
|
| Razoxane | 1 | 1996 | 10 | 0.130 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 68 | 0.130 |
Why?
|
| Cisplatin | 5 | 1995 | 256 | 0.120 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1996 | 129 | 0.120 |
Why?
|
| Cardiovascular Agents | 1 | 1996 | 85 | 0.120 |
Why?
|
| Cancer Survivors | 1 | 2018 | 187 | 0.120 |
Why?
|
| Infant | 25 | 2013 | 12322 | 0.120 |
Why?
|
| Medulloblastoma | 5 | 2013 | 335 | 0.120 |
Why?
|
| Ifosfamide | 6 | 1996 | 37 | 0.110 |
Why?
|
| Whole-Body Irradiation | 1 | 1993 | 66 | 0.110 |
Why?
|
| Humans | 63 | 2022 | 121933 | 0.110 |
Why?
|
| Education, Medical, Graduate | 2 | 2010 | 505 | 0.100 |
Why?
|
| Adolescent | 29 | 2006 | 18941 | 0.100 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 4 | 1996 | 17 | 0.100 |
Why?
|
| Glioma | 8 | 2006 | 496 | 0.100 |
Why?
|
| Bone Marrow Transplantation | 2 | 1999 | 581 | 0.100 |
Why?
|
| Lung Neoplasms | 4 | 1998 | 1613 | 0.100 |
Why?
|
| Male | 36 | 2013 | 59266 | 0.090 |
Why?
|
| Heart | 1 | 1996 | 722 | 0.090 |
Why?
|
| Adult | 26 | 2006 | 28681 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 3 | 1998 | 151 | 0.090 |
Why?
|
| Female | 35 | 2013 | 64626 | 0.090 |
Why?
|
| Schools, Medical | 1 | 2010 | 112 | 0.080 |
Why?
|
| Survival Analysis | 8 | 2006 | 1461 | 0.080 |
Why?
|
| Disease-Free Survival | 4 | 2006 | 863 | 0.080 |
Why?
|
| Leadership | 1 | 2010 | 224 | 0.070 |
Why?
|
| Pilot Projects | 4 | 1999 | 1361 | 0.070 |
Why?
|
| Osteosarcoma | 6 | 1995 | 258 | 0.070 |
Why?
|
| Rhabdoid Tumor | 2 | 1997 | 52 | 0.070 |
Why?
|
| Glioblastoma | 3 | 1996 | 327 | 0.070 |
Why?
|
| Etoposide | 3 | 1996 | 119 | 0.070 |
Why?
|
| Vincristine | 3 | 1996 | 208 | 0.070 |
Why?
|
| Drug Administration Schedule | 6 | 1998 | 729 | 0.060 |
Why?
|
| Injections, Spinal | 1 | 2005 | 115 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 157 | 0.060 |
Why?
|
| Morphine | 1 | 2005 | 88 | 0.060 |
Why?
|
| Chromosome Aberrations | 3 | 1995 | 618 | 0.060 |
Why?
|
| Headache | 1 | 2005 | 107 | 0.060 |
Why?
|
| Switzerland | 1 | 2003 | 17 | 0.060 |
Why?
|
| Affect | 1 | 2005 | 154 | 0.060 |
Why?
|
| Misonidazole | 1 | 1983 | 2 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 1999 | 146 | 0.060 |
Why?
|
| Survival Rate | 7 | 1999 | 1984 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2005 | 274 | 0.050 |
Why?
|
| Nitroimidazoles | 1 | 1983 | 52 | 0.050 |
Why?
|
| Survivorship | 1 | 2022 | 26 | 0.050 |
Why?
|
| Workload | 1 | 2003 | 145 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2005 | 379 | 0.050 |
Why?
|
| Pain | 1 | 2005 | 450 | 0.050 |
Why?
|
| Carrier Proteins | 4 | 2006 | 1022 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2005 | 396 | 0.050 |
Why?
|
| Follow-Up Studies | 8 | 1998 | 4990 | 0.040 |
Why?
|
| Mesna | 3 | 1989 | 10 | 0.040 |
Why?
|
| Pinealoma | 2 | 1999 | 18 | 0.040 |
Why?
|
| Radiotherapy Dosage | 4 | 1996 | 185 | 0.040 |
Why?
|
| Cranial Irradiation | 2 | 1999 | 69 | 0.040 |
Why?
|
| Neurilemmoma | 4 | 1993 | 45 | 0.040 |
Why?
|
| Mercaptoethanol | 2 | 1989 | 6 | 0.040 |
Why?
|
| Kidney Diseases | 3 | 1987 | 471 | 0.040 |
Why?
|
| Age Factors | 1 | 2005 | 2771 | 0.040 |
Why?
|
| Prognosis | 8 | 1998 | 4485 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 1987 | 1381 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2018 | 122 | 0.030 |
Why?
|
| Prospective Studies | 5 | 1996 | 5912 | 0.030 |
Why?
|
| Acetylglucosaminidase | 5 | 1987 | 17 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1996 | 81 | 0.030 |
Why?
|
| Camptothecin | 1 | 1996 | 78 | 0.030 |
Why?
|
| Postoperative Period | 3 | 1998 | 330 | 0.030 |
Why?
|
| Transaminases | 1 | 1996 | 33 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1996 | 254 | 0.030 |
Why?
|
| Neoplasms, Experimental | 4 | 1983 | 215 | 0.030 |
Why?
|
| Astrocytoma | 3 | 1993 | 102 | 0.030 |
Why?
|
| Pineal Gland | 1 | 1995 | 16 | 0.030 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 1995 | 9 | 0.030 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 1995 | 15 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2018 | 376 | 0.030 |
Why?
|
| Karyotyping | 3 | 1995 | 337 | 0.030 |
Why?
|
| Thymus Gland | 1 | 1995 | 101 | 0.030 |
Why?
|
| Neutropenia | 1 | 1996 | 202 | 0.030 |
Why?
|
| Aminopeptidases | 4 | 1987 | 19 | 0.030 |
Why?
|
| CD13 Antigens | 4 | 1987 | 15 | 0.030 |
Why?
|
| Drug Evaluation | 6 | 1992 | 111 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 1994 | 123 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 1993 | 1980 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 1991 | 62 | 0.030 |
Why?
|
| Ganglioglioma | 1 | 1994 | 24 | 0.030 |
Why?
|
| Foot | 1 | 1994 | 60 | 0.030 |
Why?
|
| Proteinuria | 4 | 1987 | 108 | 0.030 |
Why?
|
| Stroke Volume | 1 | 1996 | 446 | 0.030 |
Why?
|
| Nevus, Pigmented | 1 | 1993 | 33 | 0.030 |
Why?
|
| Nitrosourea Compounds | 2 | 1983 | 4 | 0.030 |
Why?
|
| Ethylnitrosourea | 2 | 1983 | 12 | 0.030 |
Why?
|
| Pneumonectomy | 1 | 1995 | 140 | 0.030 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1993 | 31 | 0.030 |
Why?
|
| Hand | 1 | 1994 | 101 | 0.030 |
Why?
|
| Supratentorial Neoplasms | 1 | 2013 | 37 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2013 | 11702 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2003 | 1150 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 1994 | 670 | 0.030 |
Why?
|
| Cholecystokinin | 1 | 1992 | 14 | 0.030 |
Why?
|
| Blood-Brain Barrier | 2 | 1983 | 141 | 0.030 |
Why?
|
| Carcinoma | 1 | 1995 | 282 | 0.030 |
Why?
|
| Pentetic Acid | 1 | 1992 | 10 | 0.030 |
Why?
|
| Topotecan | 2 | 2006 | 49 | 0.030 |
Why?
|
| Meglumine | 1 | 1992 | 15 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 1992 | 48 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 1994 | 417 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1995 | 470 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 3 | 1983 | 431 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 1992 | 106 | 0.020 |
Why?
|
| Osteotomy | 1 | 1991 | 40 | 0.020 |
Why?
|
| Extremities | 1 | 1991 | 82 | 0.020 |
Why?
|
| Hot Temperature | 1 | 1971 | 135 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1992 | 265 | 0.020 |
Why?
|
| Thoracotomy | 1 | 1992 | 111 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1242 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 1993 | 1116 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 1992 | 193 | 0.020 |
Why?
|
| Professional Competence | 1 | 2010 | 96 | 0.020 |
Why?
|
| Methotrexate | 2 | 1990 | 341 | 0.020 |
Why?
|
| Heart Rate | 1 | 1971 | 584 | 0.020 |
Why?
|
| Contrast Media | 1 | 1992 | 452 | 0.020 |
Why?
|
| Aging | 1 | 1995 | 1160 | 0.020 |
Why?
|
| Hospitalization | 1 | 1996 | 1724 | 0.020 |
Why?
|
| Fibroma | 1 | 1987 | 30 | 0.020 |
Why?
|
| Creatinine | 2 | 1987 | 376 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 1996 | 1082 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 1987 | 29 | 0.020 |
Why?
|
| Thymectomy | 1 | 1987 | 24 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 1999 | 8103 | 0.020 |
Why?
|
| Autoradiography | 2 | 1983 | 72 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1992 | 2008 | 0.020 |
Why?
|
| Blood | 1 | 1987 | 106 | 0.020 |
Why?
|
| Rats, Inbred F344 | 2 | 1983 | 104 | 0.020 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 1999 | 52 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 1986 | 650 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 1993 | 3437 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 1993 | 802 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1987 | 317 | 0.020 |
Why?
|
| Procarbazine | 1 | 2006 | 13 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1987 | 402 | 0.020 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2006 | 37 | 0.020 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2006 | 18 | 0.020 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2006 | 54 | 0.020 |
Why?
|
| Nervous System | 1 | 1987 | 130 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 1987 | 375 | 0.020 |
Why?
|
| Regional Blood Flow | 2 | 1983 | 205 | 0.020 |
Why?
|
| Tissue Distribution | 2 | 1983 | 382 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1987 | 304 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 1999 | 370 | 0.020 |
Why?
|
| Chromosomes, Human, 1-3 | 1 | 1985 | 2 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 1995 | 1681 | 0.020 |
Why?
|
| Child Development | 1 | 1988 | 249 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2006 | 122 | 0.020 |
Why?
|
| Preoperative Care | 1 | 1987 | 346 | 0.020 |
Why?
|
| Cell Division | 1 | 1987 | 796 | 0.020 |
Why?
|
| Rats | 4 | 1983 | 3655 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1992 | 1890 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1987 | 816 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1996 | 2381 | 0.010 |
Why?
|
| Lung | 1 | 1992 | 1471 | 0.010 |
Why?
|
| Treatment Failure | 2 | 1995 | 332 | 0.010 |
Why?
|
| Neoplasm Staging | 3 | 1994 | 1226 | 0.010 |
Why?
|
| Heart Failure | 1 | 1996 | 2122 | 0.010 |
Why?
|
| Proportional Hazards Models | 2 | 1998 | 1283 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 525 | 0.010 |
Why?
|
| Infusions, Intravenous | 2 | 1996 | 539 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1711 | 0.010 |
Why?
|
| Life Tables | 2 | 1991 | 26 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 1992 | 1075 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2010 | 15630 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 1283 | 0.010 |
Why?
|
| Recurrence | 2 | 1994 | 1396 | 0.010 |
Why?
|
| Aneuploidy | 2 | 1992 | 156 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1999 | 259 | 0.010 |
Why?
|
| Fluorouracil | 2 | 1990 | 141 | 0.010 |
Why?
|
| Drug Synergism | 2 | 1990 | 233 | 0.010 |
Why?
|
| Animals | 5 | 1987 | 33736 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 1999 | 193 | 0.010 |
Why?
|
| Growth Disorders | 1 | 1999 | 209 | 0.010 |
Why?
|
| Time Factors | 3 | 1994 | 5997 | 0.010 |
Why?
|
| Incidence | 2 | 1996 | 2997 | 0.010 |
Why?
|
| Age Distribution | 1 | 1998 | 399 | 0.010 |
Why?
|
| Dipeptidyl Peptidase 4 | 2 | 1986 | 21 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1996 | 69 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1997 | 354 | 0.010 |
Why?
|
| Dacarbazine | 2 | 1987 | 85 | 0.010 |
Why?
|
| Brain Stem | 1 | 1996 | 118 | 0.010 |
Why?
|
| Reoperation | 1 | 1998 | 771 | 0.010 |
Why?
|
| Leukocyte Common Antigens | 1 | 1995 | 91 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 1994 | 114 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1995 | 231 | 0.010 |
Why?
|
| Risk | 1 | 1996 | 743 | 0.010 |
Why?
|
| Gliosarcoma | 1 | 1994 | 10 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1994 | 28 | 0.010 |
Why?
|
| Opportunistic Infections | 1 | 1994 | 78 | 0.010 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 1994 | 37 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1994 | 268 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 1994 | 102 | 0.010 |
Why?
|
| Oligodendroglioma | 2 | 1983 | 23 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1994 | 334 | 0.010 |
Why?
|
| Aminoisobutyric Acids | 2 | 1983 | 8 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1994 | 256 | 0.010 |
Why?
|
| Rats, Inbred Strains | 2 | 1983 | 229 | 0.010 |
Why?
|
| Craniotomy | 1 | 1994 | 108 | 0.010 |
Why?
|
| Mitosis | 1 | 1994 | 239 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1995 | 162 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 1992 | 50 | 0.010 |
Why?
|
| Meningioma | 1 | 1994 | 110 | 0.010 |
Why?
|
| Myelography | 1 | 1992 | 8 | 0.010 |
Why?
|
| Meningeal Neoplasms | 1 | 1994 | 173 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1992 | 393 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1992 | 138 | 0.010 |
Why?
|
| Oncogenes | 1 | 1992 | 172 | 0.010 |
Why?
|
| Skin Temperature | 1 | 1971 | 19 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1993 | 609 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 1991 | 151 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1992 | 971 | 0.010 |
Why?
|
| Fetal Heart | 1 | 1971 | 111 | 0.010 |
Why?
|
| Leucovorin | 1 | 1990 | 50 | 0.010 |
Why?
|
| Cerebellar Neoplasms | 1 | 1993 | 280 | 0.010 |
Why?
|
| Mice | 1 | 1987 | 17547 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1991 | 755 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1992 | 1068 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 1995 | 2059 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1990 | 337 | 0.010 |
Why?
|
| Risk Assessment | 1 | 1998 | 3223 | 0.010 |
Why?
|
| Remission Induction | 1 | 1989 | 301 | 0.000 |
Why?
|
| Dactinomycin | 1 | 1987 | 68 | 0.000 |
Why?
|
| Brain | 2 | 1994 | 2945 | 0.000 |
Why?
|
| Immunochemistry | 1 | 1986 | 31 | 0.000 |
Why?
|
| Saline Solution, Hypertonic | 1 | 1987 | 20 | 0.000 |
Why?
|
| Carboplatin | 1 | 1987 | 78 | 0.000 |
Why?
|
| Osmolar Concentration | 1 | 1986 | 173 | 0.000 |
Why?
|
| Urologic Diseases | 1 | 1987 | 44 | 0.000 |
Why?
|
| Biomarkers, Tumor | 1 | 1994 | 1424 | 0.000 |
Why?
|
| Hematologic Diseases | 1 | 1987 | 74 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1992 | 2828 | 0.000 |
Why?
|
| Embryonal Carcinoma Stem Cells | 1 | 1985 | 10 | 0.000 |
Why?
|
| Clone Cells | 1 | 1985 | 167 | 0.000 |
Why?
|
| Wilms Tumor | 1 | 1985 | 112 | 0.000 |
Why?
|
| Acute Disease | 1 | 1987 | 1086 | 0.000 |
Why?
|
| Lymphoma | 1 | 1987 | 325 | 0.000 |
Why?
|
| Methylnitrosourea | 1 | 1983 | 19 | 0.000 |
Why?
|
| Choroid Plexus | 1 | 1983 | 23 | 0.000 |
Why?
|
| Subarachnoid Space | 1 | 1983 | 24 | 0.000 |
Why?
|
| Capillary Permeability | 1 | 1983 | 78 | 0.000 |
Why?
|
| Neoplastic Stem Cells | 1 | 1985 | 294 | 0.000 |
Why?
|
| Nervous System Diseases | 1 | 1987 | 372 | 0.000 |
Why?
|
| Biological Transport | 1 | 1983 | 348 | 0.000 |
Why?
|
| Head and Neck Neoplasms | 1 | 1987 | 469 | 0.000 |
Why?
|
| Chromosome Deletion | 1 | 1985 | 636 | 0.000 |
Why?
|
| Blood Flow Velocity | 1 | 1983 | 446 | 0.000 |
Why?
|
| Kinetics | 1 | 1983 | 1317 | 0.000 |
Why?
|
| Pregnancy | 2 | 1983 | 7082 | 0.000 |
Why?
|
| Hippocampus | 1 | 1983 | 806 | 0.000 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1985 | 953 | 0.000 |
Why?
|
| Middle Aged | 1 | 1994 | 25447 | 0.000 |
Why?
|